Figure 5 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification

Figure 5 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification

<p>PTEN and RB loss in HGSOC. <b>A,</b> Frequency of loss of PTEN protein expression across HRR-centric subtypes. <b>B,</b> Frequency of loss of RB protein expression across HRR-centric subtypes. <b>C,</b> Impact of RB loss on survival in patients based on H...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awdur: Robert L. Hollis (15034814) (author)
Awduron Eraill: Alison M. Meynert (14956260) (author), Caroline O. Michie (15043392) (author), Tzyvia Rye (4733277) (author), Michael Churchman (15034811) (author), Amelia Hallas-Potts (15043395) (author), Ian Croy (15034823) (author), W. Glenn McCluggage (8775452) (author), Alistair R.W. Williams (15043398) (author), Clare Bartos (15034820) (author), Yasushi Iida (4097272) (author), Aikou Okamoto (14957624) (author), Brian Dougherty (108958) (author), J. Carl Barrett (11900099) (author), Ruth March (73809) (author), Athena Matakidou (15034847) (author), Patricia Roxburgh (14961464) (author), Colin A. Semple (15034853) (author), D. Paul Harkin (14873531) (author), Richard Kennedy (248483) (author), C. Simon Herrington (15034817) (author), Charlie Gourley (15034850) (author)
Cyhoeddwyd: 2025
Pynciau:
Cancer
Cancer Biology
Tumor Biology
Therapeutic Research and Development
Clinical Research and Trials
Gynecological Cancers
Ovarian cancer
Oncogenes & Tumor Suppressors
BRCA family
Precision Medicine
Translational Research
Tumor Microenvironment
Immune cells and the microenvironment
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
Disgrifiad
Crynodeb:<p>PTEN and RB loss in HGSOC. <b>A,</b> Frequency of loss of PTEN protein expression across HRR-centric subtypes. <b>B,</b> Frequency of loss of RB protein expression across HRR-centric subtypes. <b>C,</b> Impact of RB loss on survival in patients based on HRR status. Multivariable hazard ratio (mHR) for HRR-ab: RB loss vs. HRR-ab RB-intact = 0.50; 95% CI, 0.30–0.84; mHR for HRRwt/<i>CCNE1</i>g: RB loss vs. HRRwt/<i>CCNE1</i>g: RB-intact = 0.71; 95% CI, 0.48–1.06. <i>BRCA2</i>m, <i>BRCA2</i> mutant; <i>BRCA1</i>m, <i>BRCA1</i> mutant; <i>EMSY</i>-overxp; overexpression of <i>EMSY</i>; nBRCA-HRRm, non-<i>BRCA1</i>/<i>2</i> HRR gene mutation; <i>CCNE1</i>g, gain of <i>CCNE1</i>; HRRwt, non-<i>CCNE1</i>g HRR wild-type. HRR-ab, HRR-aberrant: <i>BRCA1</i>m, <i>BRCA2</i>m, <i>EMSY</i>-overxp, or n<i>BRCA</i>-HRRm.</p>

Eitemau Tebyg